Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.
Palandri F, Branzanti F, Morsia E, Dedola A, Benevolo G, Tiribelli M, Beggiato E, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Isidori A, Scalzulli E, D'Agostino D, Caserta S, Nardo A, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Palumbo GA, Breccia M, Elli EM, Bonifacio M.
Palandri F, et al. Among authors: farina m.
Ann Hematol. 2025 Jan 20. doi: 10.1007/s00277-025-06204-5. Online ahead of print.
Ann Hematol. 2025.
PMID: 39831987